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Objectives: To collect health care resource utilization (HCRU) in the management 
of idiopathic pulmonary fibrosis (IPF) patients. MethOds: A retrospective, longi-
tudinal, cohort study design via chart review analysis of anonymized IPF patient 
records is being conducted in order to collect healthcare resource data from a major 
IPF treatment centre in Ontario, Canada. A convenience sample of 90 IPF patients 
was selected with inclusion criteria of adult age at diagnosis having a confirmed 
diagnosis of IPF, and minimum of one respirologist visit. Demographics and HCRU 
data were collected with descriptive statistics to be presented. Costs are presented 
in 2014 Canadian dollars. Results: For the preliminary analysis, 45 IPF patients 
met the study inclusion criteria. 30 were male with the mean age at diagnosis 
being 71.3 years (range 39-89 years). Information about IPF treatments, supportive 
medications, tests/procedures, physician visits and hospitalizations were obtained 
from the charts. The overall cost of the cohort was $873,936, with a mean cost per 
patient of $19,421 ($986-$117,004, ±$18,961). The 30 day cost per patient was $337. 
IPF treatments accounted for more than half the total cost ($494,416). Patients were 
stratified by disease severity at diagnosis and followed over progression. 33 were 
diagnosed as initially having mild disease, and 12 had moderate disease. Patients 
with mild disease were followed an average of 65.8 months and had an average 
per patient cost of $20,029 (30 day cost: $305). Moderate patients were followed 
an average of 35.0 months and had an average per patient cost of $17,747 (30 day 
cost: $592). cOnclusiOns: Preliminary results from a major IPF treatment centre 
indicate substantial HCRU associated with IPF management. The authors plan to 
complete data extraction at the centre in order to determine HCRU and cost results 
for the full cohort.
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Objectives: Fixed-dose combinations (FDCs) of inhaled corticosteroids (ICS) and 
long-acting beta agonists (LABA) are recommended in moderate to severe persis-
tent asthma and chronic obstructive pulmonary disease (COPD). The aim of the 
analysis was to evaluate the clinical and economic burden of asthma and COPD in 
Poland, and assess the impact of poor inhalation technique with ICS + LABA FDCs 
- which is common with inhalers - reimbursed in Poland on costs and resource 
use. MethOds: The eligible patient population was estimated based on Polish 
asthma and COPD prevalence rates, with the proportion of patients receiving FDCs 
based on available National Health Fund (NHF) data. Costs of inhalers, scheduled 
and unscheduled health care events were taken from publicly available sources. The 
analysis was conducted in one-year horizon from the payer and patient perspective 
(direct costs) and societal perspective (indirect costs). Frequency of poor inhalation 
technique (occurrence of critical inhaler errors) and the associated increased risk 
of unscheduled health care events were estimated based on a large (N = 1,664), 
cross-sectional, observational study, performed in Italy in 2008. Results: In Poland 
207,801 adults with asthma and COPD receive an ICS + LABA FDCs annually, of which 
56,937 are estimated to have poor inhalation technique. Total direct costs were 
estimated to be 378 million PLN (91.1 million EUR)and productivity loss costs – 20.4 
million PLN (4.9 million EUR) cOnclusiOns: The clinical and economic burden 
of asthma and COPD is considerable in Poland and poor inhalation technique is a 
substantial contributor to costs of unscheduled healthcare events. Novel inhalers 
with easier inhalation technique may offer clinical and economic benefits in the 
management of asthma and COPD.
PRS35
nEW CoPd mEdiCinal PRoduCtS EntRanCE analySiS and thEiR 
influEnCE on thE numBER and CoSt of hoSPitalizatonS duE to CoPd 
ExaCERBationS
Dimitrova M1, Kamusheva M1, Mitov K1, Petkova V1, Dimitrov J2, Petrova G1
1Medical University Sofia, Faculty of Pharmacy, Sofia, Bulgaria, 2University Hospital for 
specialized treatment of pulmonary diseases, Sofia, Bulgaria
Objectives: To perform an analysis of the changes in the number and cost of hospi-
talizations of COPD patients after the introduction of the new inhalation medicines 
into the Positive drug list (PDL). MethOds: It is retrospective, real life observational 
study on the hospitalizations of COPD patients due to exacerbations and the inclusion 
of new medicinal products for the treatment of COPD in PDL for a 6-year period (2009-
2014). Data for the number of hospitalizations due to COPD exacerbations, their cost, 
and the number of COPD patients with valid health insurance status was collected 
from National Health Insurance Fund (NHIF). Newly entered medicinal products for 
COPD were extracted from the PDL. Macro-costing approach was applied to evalu-
ate the total medical costs on hospitalizations. Statistical processing was through 
Spearman and Pearson correlation, and Freedman test. Results: Before 2009 COPD 
pharmacotherapy was partially reimbursed by NHIF. ICS/LABA were included with 
100% reimbursement and LAMA with 75% in PDL in 2010. In 2013 and 2014 in PDL 
were included glycopyrronim, aclidinium and indacaterol/glycopyrronium with 75% 
reimbursement and two generic ICS/LABA with 100% reimbursement. A statistically 
significant decrease in the hospitalizations due to COPD exacerbations was observed 
– from 28% in 2009 to 19% in 2014 (p< 0.0001). On the other hand, there is an increase 
in the total cost of hospitalizations mostly due to the increase in the cost of hospital 
services. Statistically significant correlation with linear nature exists also between 
the number of hospitalizations and the number of health-insured patients with COPD. 
Increase in the number of health insured let to the increase in the hospitalizations 
resource utilization and cost to determine whether functional decline is associated 
with increased healthcare resource utilization and costs. MethOds: Medicare and 
commercial patients who received an endothelin-receptor antagonist (ERA), phospho-
diesterase type 5 inhibitor (PDE5) or prostacyclin (PG12) and reported a medical claim 
with an ICD-9-CM of 416.0, 416.8 or 416.9 or a medical claim indicating right heart 
catheterization (RHC) were identified from pharmacy and medical claims data from 
2009 through 2013. The date of initial therapy served as the index date. Using provider-
reported data from prior authorization forms required for prescribing advanced PAH 
therapies listed above, the WHO-FC was found for 437 patients (FCII= 99; FCIII= 282; 
FCIV= 56). Results: Linear models indicated that the FCIV cohort averaged signifi-
cantly more inpatient admissions (Ps< 0.001), longer lengths of stay (Ps< 0.01) and 
more ER visits (Ps< 0.01) than the FCII or FCIII cohorts. Costs analyses indicated that 
FCIV had significantly higher medical costs than FCII ($130,572/year vs $120,588/year) 
(P= 0.002) and significantly higher total costs (pharmacy + medical) ($180,828/year vs 
$162,072/year) (P= 0.004). cOnclusiOns: PAH patients demonstrated a high level of 
utilization and costs. Disease severity, indicated by WHO-FC, is associated with higher 
utilization and costs for FCIV patients. Only small differences were found between 
FCII and FCIII. The FCIII cohort was twice as large as the FCII cohort. This suggests 
difficulty differentiating between these two FCs and potential bias in the sampling 
when relying on the prior authorization form for this clinical information.
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Objectives: The Continuing to Confront COPD International Patient Survey 
estimated the prevalence and burden of chronic obstructive pulmonary disease 
(COPD) across 12 countries. The objective of this sub-study was to estimate the 
humanistic and economic burden associated with dyspnoea in Spanish patients 
with COPD. MethOds: Spanish COPD patients from a cross-sectional population-
based survey conducted between November 2012 and May 2013, including subjects 
> 40 years fulfilling a case-definition of COPD based on a self-reported physician 
diagnosis or symptomatology were included. Patients were further classified as no/
mild dyspnoea (mMRC < 2) and moderate/severe dyspnoea (mMRC > 2), according 
to modified Medical Council Scale (mMRC) score. Impact of dyspnoea on health-
related quality of life (QoL) measured with COPD Assessment Test (CAT) and costs 
were compared between the two groups. Direct healthcare costs included moderate 
(community treated) and severe COPD exacerbations (requiring emergency room 
visits and/or hospitalization), primary care visits, COPD treatment including oxygen 
use, and immunization in the previous 12 months. Indirect costs included work loss 
estimated using the Work Productivity and Activity Impairment Scale. Results: 303 
Spanish subjects were included; mean age 65.1 years old, 57% male and 73.6% self-
reported moderate to very severe COPD. 47.1% of the subjects included were classi-
fied as having moderate/severe dyspnoea. These dyspnoeic patients showed a higher 
impact on QoL (CAT score > 20): 57.2% vs 28.8%, as well as higher costs than patients 
reporting no/mild dyspnoea: direct costs: 3,938€ vs 1,818€ (p< 0.001), indirect costs: 
3,596€ vs 3,011€ (p= 0.426), societal costs: 7,534€ vs 4,828€ (p= 0.004). cOnclusiOns: 
The frequency of moderate/severe dyspnoea is high among Spanish COPD patients. 
Dysponea was associated with higher impact on QoL and higher societal costs. 
Healthcare strategies targeted to improve dyspnoea symptoms could reduce the 
burden associated with COPD.
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Objectives: The current project aims to (1) evaluate cost burden of smoking to Asia 
and (2) increase public awareness on smoking and its clinical and economic impact 
to the society. MethOds: This is a retrospective literature review aiming to inves-
tigate the published work related to the burden of smoking to smokers since 2000. 
All published articles related to cost of smoking were reviewed. The current costs 
of each pack of cigarettes in the target Asia-Pacific countries (Hong Kong, Malaysia, 
Thailand, Philippines, South Korea, Singapore and Australia) were documented. Both 
tobacco cost per smoker (out-of-pocket) and the direct health care cost per smoker 
were estimated. The prevalence of smokers in each country was documented and 
for the calculation of the out-of-pocket cost per each smoker based on published 
data. The direct health care expenditure was documented based on the published 
data. We also estimated the cost of saving if the smoker stops smoking accord-
ing to the specific age and the expected life expectancy in each country. All cost 
estimation was based on the year 2014. Results: In 2014, the estimated annual 
government expenditure on managing smoking related diseases was Hong Kong 
(USD 1.45 billion), Malaysia (USD 1.11 billion), Thailand (USD 8.48 billion), Philippines 
(USD 7.70 billion), South Korea (USD 1.61 billion), Singapore (USD 0.72 billion) and 
Australia (USD 1.69 billion). Among the 7 countries, the smokers spend the most 
in Australia, Singapore and Hong Kong. The annual out-of-pocket cost for smokers 
for one pack per day was Hong Kong (USD 2620), Malaysia (USD 1460), Thailand 
(USD 1095), Philippines (USD 511), South Korea (USD 1825), Singapore (USD 3650) 
and Australia (USD 6935). cOnclusiOns: The cost burden of smoking is high from 
both smokers and government perspectives. Reduction of the smoking population 
can significantly alleviate the disease burden and reduce public health expenditure.
PRS33
Examining hEalth SyStEm and RESouRCE utilization and mEdiCal 
managEmEnt of PatiEntS idioPathiC PulmonaRy fiBRoSiS in ontaRio: a 
PREliminaRy analySiS
Mittmann N1, Hassan S1, Seung SJ1, Saherawala H1, Hoffstein V2, Bradley-Kennedy C3
